Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (October 20th Preview)
-
FDA accelerates Jemperli label for rectal cancer
GSK’s cancer immunotherapy Jemperli (dostarlimab) received an accelerated FDA approval for advanced rectal cancer patients with a specific genetic signature, expanding beyond the drug’s initial endometrial cancer indication. The label expansion follows the company’s clinical development program in mismatch-repair biology-driven colorectal disease. For biopharma stakeholders, the approval adds a new on-label use case for a PD-1 axis antibody and underscores continued regulatory receptivity to biomarker-defined cancer populations. It also adds competitive intensity to the immunotherapy landscape in rectal cancer, where treatment selection increasingly hinges on tumor molecular features. While accelerated approvals can carry confirmatory obligations, the immediate commercial implication is clear: prescribers and payers will begin operationalizing a new genetic test workflow tied to access and reimbursement decisions.
-
Genmab bets on Epkinly and ADC pipeline as Darzalex revenue cliff nears
Genmab is positioning its next catalyst slate as its Darzalex revenue stream faces major patent-loss exposure. The company’s strategy hinges on late-stage and near-term readouts for multiple oncology programs, including Epkinly in first-line lymphoma and ADC assets such as rinatabart sesutecan (Rina-S), alongside the bispecific petosemtamab acquired in Genmab’s Merus deal. With Darzalex royalties projected to shrink materially after patent expirations, the near-term clinical data calendar is framed as pivotal for whether Genmab can sustain growth beyond the so-called “cliff” period. Analysts highlighted Epkinly and Rina-S as key validation points, while petosemtamab is described as the most important ramp candidate. The update matters for investors and partners evaluating the stability of Genmab’s pipeline economics as a core franchise transitions from protection to renewal.
-
Gilead advances oral a4β7 integrin asset emvistegrast after SWIFT Phase 2 win
Gilead reported positive Phase 2 results for emvistegrast, delivering higher clinical response rates than placebo in moderately to severely active ulcerative colitis in the SWIFT trial. In the highest-dose cohort, 66% of patients achieved clinical response versus 37% with placebo, and the study met its primary endpoint on nominal significance. The results set up Phase 3 planning and also support additional development in Crohn’s disease and potential combination studies, with Gilead framing emvistegrast as a competitive oral option within the a4β7 integrin class. For competitors and payers, the key operational question will be dosing strategy, durability of response, and where an oral integrin blocker lands relative to established biologic administration routes.
-
Merck KGaA expands rare-disease hematology with Silence Therapeutics deal
Merck KGaA agreed to acquire Silence Therapeutics for $1.3 billion in an all-cash transaction, adding a late-stage rare blood-cancer siRNA program to its pipeline. The purchase brings Divesiran, an RNAi candidate targeting TMPRSS6 in polycythemia vera to raise hepcidin and limit iron availability for red blood cell production. Merck said the deal strengthens its capabilities in targeted specialty and rare diseases, with closing expected in the first quarter of 2027. Silence and Merck will remain independent until the transaction completes, but the asset adds a mechanism of action distinct from standard PV approaches like phlebotomy and cytoreductive therapy. Strategically, the acquisition signals continued demand for clinically focused RNAi platforms in hematology and a push to add assets that can differentiate against chronic, high-burden care pathways.
-
China partnership: Roche and Hansoh co-develop antibody-drug conjugates
Hansoh Pharmaceutical struck a deal with Roche to develop a portfolio of antibody-drug conjugates, extending Roche’s reach into China-powered discovery and development execution. The arrangement is positioned as co-development, reflecting how large pharma is pairing global late-stage expertise with regional early pipeline acceleration. The transaction reinforces the competitive pressure on CDMO and development ecosystems in China, particularly as ADC manufacturing scale-up and analytical development become central bottlenecks. For partners, the deal suggests continued prioritization of mechanistically diverse ADC payload and linker strategies. From a business perspective, the Roche-Hansoh collaboration is another data point in how global majors are structuring cross-border co-development to preserve speed while managing IP and regulatory pathways.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.